• 作者：Xiaoyan Sun^a ; ^b ; ^{XXS356@med.miami.edu" class="auth_mail" title="E-mail the corresponding author} ; Chuanhui Dong^a ; ^b ; Bonnie Levin^a ; ^b ; Elizabeth Crocco^c ; David Loewenstein^c ; Henrik Zetterberg^d ; ^e ; ^f ; Kaj Blennow^d ; ^f ; Clinton B. Wright^a ; ^b ; ; the Alzheimer's Disease Neuroimaging Initiative
• 关键词：Synaptic function ; Neurogranin ; APOE ε4 ; Alzheimer's disease ; APOE ; Mild cognitive impairment
• 刊名：Alzheimer's & Dementia
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：12
• 期：11
• 页码：1159-1166
• 全文大小：744 K

Methods

We compared levels of CSF neurogranin (Ng) between APOE ε4 carriers and noncarriers in 399 subjects with normal cognition, mild cognitive impairment (MCI), and AD. We examined associations between Ng levels and age, education, gender, CSF-Aβ42, and tau protein.

Results

Neurogranin levels were significantly higher in APOE ε4 carriers compared to APOE ε4 noncarriers with MCI. Levels of Ng between the APOE ε4 carriers and APOE ε4 noncarriers with AD did not differ. Ng levels were correlated with MMSE and levels of tau and Aβ42.

Discussion

Significantly higher CSF Ng levels in APOE ε4 carriers with MCI may reflect synaptic injury underlying early cognitive impairment. Neurogranin may be an early biomarker of AD and important for disease diagnosis and timing of intervention in APOE ε4 carriers.